BeyondSpring Inc.
BYSIBeyondSpring Inc. in brief
BeyondSpring Inc. is a listed company in the Biotechnology industry, based in Florham Park, New Jersey, USA. It was founded in 2010. Its market value was $22 M on 30 October 2026, which makes it the 24,101st largest listed company in the world and the 4,139th largest in the USA on this site. Min Qiu is its chief executive. Its shares trade under the symbol BYSI (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About BeyondSpring Inc.
BeyondSpring is an Innovative Immuno Oncology Cancer Therapies company with a robust pipeline from internal development and collaboration with the University of Washington in de novo drug discovery using an ubiquitination platform. It is having 91 employees as on 2020. The headquarters is in USA.
BeyondSpring Inc. timeline
- 2010
- 🏁· approximateFounded
- 2016
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2017
- 🔔Initial public offering on NasdaqFinal prospectus filed with the SEC on 9 March 2017; shares registered for exchange trading on 6 March 2017.
Events of BeyondSpring Inc. from the company record and SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #2,655 (Jan 2020) · #2,784 (Jan 2021) · #3,951 (Jan 2022) · #4,747 (Dec 2022) · #4,850 (Jul 2023) · #4,206 (Jan 2024) · #2,104 (Mar 2026) · #3,828 (Aug 2026) · #4,060 (Oct 2026) · #4,142 (Oct 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- -92.1%
- Net margin
- —
- Operating margin
- —
- Return on equity
- —
- Liabilities / assets
- 192.5%
- Net debt
- $-42M
- Revenue growth
- 0.0%
- R&D / revenue
- 1894.8%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-9M | $-1M | — |
| Dec 2024 | — | — | $-9M | $-11M | — |
| Dec 2023 | — | — | $-15M | $-21M | — |
| Dec 2022 | $1M | 0.0% | $-37M | $-33M | -2465.2% |
| Dec 2021 | $1M | — | $-66M | $-64M | -4754.1% |
| Dec 2020 | — | — | $-64M | $-61M | — |
| Dec 2019 | — | — | $-40M | $-38M | — |
| Dec 2018 | — | — | $-58M | $-55M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-20M | $0M | $-20M | — | — |
| Dec 2024 | $-16M | $0M | $-17M | — | — |
| Dec 2023 | $-16M | $0M | $-17M | — | — |
| Dec 2022 | $-27M | $0M | $-27M | — | — |
| Dec 2021 | $-47M | $3M | $-50M | $-1.64 | — |
| Dec 2020 | $-44M | $0M | $-44M | $-2.03 | — |
| Dec 2019 | $-48M | $0M | $-48M | $-1.55 | — |
| Dec 2018 | $-40M | $0M | $-40M | $-2.42 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-1M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 13, 20268-KCurrent reportShareholder vote
- Oct 6, 20268-KCurrent reportAcquisition or disposal completed
- Oct 2, 20268-KCurrent reportListing notice
- Sep 29, 20268-KCurrent reportMaterial agreement · Other events
- Sep 18, 20268-KCurrent reportListing notice
- Sep 3, 2026DEF 14AProxy statement
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 14, 20268-KCurrent reportResults of operations
- Jun 29, 20268-K/ACurrent report (amended)Directors or officers changed
- Jun 4, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- May 13, 202610-QQuarterly report · period to Mar 2026
- May 13, 20268-KCurrent reportResults of operations
Official filings of BeyondSpring Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-9 M
- Net income
- $-1 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $26 M
- Total liabilities
- $50 M
- Total equity
- $-32 M
As of December-2025
Top 19 institutional investors in BeyondSpring Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Decheng Capital LLC | 3,065,702 | -735,000 (-19.34%) | 7.46% | $2 M | Nov 13, 2026 |
| 2 | Vanguard Capital Management LLC | 695,207 | +68,750 (+10.97%) | 1.69% | $1 M | Nov 13, 2026 |
| 3 | BlackRock, Inc. | 668,863 | -4,052 (-0.60%) | 1.63% | $1 M | Nov 13, 2026 |
| 4 | Geode Capital Management, LLC | 367,740 | 0 (0.00%) | 0.89% | $0 M | Nov 6, 2026 |
| 5 | State Street Corp | 259,320 | +28,200 (+12.20%) | 0.63% | $0 M | Nov 12, 2026 |
| 6 | Vanguard Fiduciary Trust Co | 181,196 | 0 (0.00%) | 0.44% | $0 M | Nov 13, 2026 |
| 7 | Northern Trust Corp | 62,024 | 0 (0.00%) | 0.15% | $0 M | Nov 16, 2026 |
| 8 | UBS Group AG | 53,702 | -9,330 (-14.80%) | 0.13% | $0 M | Nov 10, 2026 |
| 9 | Citadel Advisors LLC | 13,605 | New | 0.03% | $0 M | Nov 16, 2026 |
| 10 | Meridian Wealth Management, LLC | 10,000 | -5,000 (-33.33%) | 0.02% | $0 M | Nov 5, 2026 |
| 11 | Vanguard Global Advisers, LLC | 4,802 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 12 | Morgan Stanley | 4,570 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 13 | National Bank Of Canada /fi/ | 2,875 | 0 (0.00%) | 0.01% | $0 M | Nov 16, 2026 |
| 14 | Trifecta Capital Advisors, LLC | 1,500 | 0 (0.00%) | 0.00% | $0 M | Oct 21, 2026 |
| 15 | Simplex Trading, LLC | 929 | -236 (-20.26%) | 0.00% | $0 M | Nov 4, 2026 |
| 16 | Jpmorgan Chase & Co | 495 | +176 (+55.17%) | 0.00% | $0 M | Nov 12, 2026 |
| 17 | Jones Financial Companies Lllp | 98 | New | 0.00% | $0 M | Nov 13, 2026 |
| 18 | SBI Securities Co., Ltd. | 76 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 19 | Caitong International Asset Management Co., Ltd | 1 | 0 (0.00%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding BeyondSpring Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 343,113 | $1 M | 0.83% | <0.01% | −0.4% | Jun 30, 2026 |
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 282,669 | $0 M | 0.69% | <0.01% | +7.3% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 164,922 | $0 M | 0.40% | <0.01% | +2.9% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 105,492 | $0 M | 0.26% | 0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 66,108 | $0 M | 0.16% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 42,932 | $0 M | 0.10% | <0.01% | +3.1% | May 31, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 23,601 | $0 M | 0.06% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 7,272 | $0 M | 0.02% | <0.01% | +20% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 8 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at BeyondSpring Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Lan HuangChief Executive Officer, Director, 10% owner | Giftindirect | -260,582 | — | —local | 0 | Form 4 |
| filed | Decheng Capital China Life Sciences USD Fund II, L.P.10% owner | Sellindirect | -45,513 | 1.760 | 80 Klocal | 1.52 M | Form 4 |
| filed | Decheng Capital China Life Sciences USD Fund II, L.P.10% owner | Sellindirect | -85,798 | 1.720 | 148 Klocal | 1.56 M | Form 4 |
| filed | Decheng Capital Global Healthcare GP, LLC10% owner | Sellindirect | -17,960 | 1.650 | 30 Klocal | 1.65 M | Form 4 |
| filed | Decheng Capital Global Healthcare GP, LLC10% owner | Sellindirect | -28,495 | 1.650 | 47 Klocal | 1.67 M | Form 4 |
| filed | Decheng Capital Global Healthcare GP, LLC10% owner | Sellindirect | -107,361 | 1.700 | 183 Klocal | 1.70 M | Form 4 |
| filed | Decheng Capital Global Healthcare GP, LLC10% owner | Sellindirect | -2,390 | 1.770 | 4 Klocal | 1.80 M | Form 4 |
| filed | Decheng Capital Global Healthcare GP, LLC10% owner | Sellindirect | -3,979 | 1.810 | 7 Klocal | 1.81 M | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals. This company files with the SEC as a foreign issuer; its insiders often report prices in the home currency, so amounts are as filed and not converted to dollars
Markets and events: BeyondSpring Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Trading halts
- 2026-08-13 16:21 UTC, code LUDP, resumed 16:26 UTC
Fails to deliver
- : 9,763 shares at $0.52
- : 536 shares at $0.52
- : 10,722 shares at $0.46
- : 10,358 shares at $0.43
- : 11,948 shares at $0.45
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
BeyondSpring Inc. scorecard#
Passes 2 of the 9 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.
Valuation0 of 4
- ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
- ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
- –Price to sales below its peers' medianNo Price to sales on file.
- ✗Free cash flow yield above 5%-92.1%Free cash flow is -92.1% of the market value.
- ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth1 of 1
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
- ✓Net income higher than five years earlier-$1 M-$1 M in fiscal 2025 against -$61 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 2
- ✗Profitable in the newest year-$1 MNet income -$1 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- –Return on equity above 15%No return on equity (equity missing or negative).
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities1.5×Current ratio 1.54 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
BeyondSpring Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 0—— | 0—— | 0−100%— | 1.40.0%100% | 1.4+651%100% | 0.2—100% | 0—— | 0—— | 0—— | 0—— | |
| Research and development | 4.4+66.0%— | 2.6−63.6%— | 7.3−71.6%— | 26−30.6%1894% | 37−11.7%2730% | 42+33.3%23218% | 31−39.3%— | 52−42.0%— | 89+752%— | 10—— | |
| Selling, general and administrative | 4.6−25.4%— | 6.1−21.8%— | 7.8−40.0%— | 13−57.6%963% | 31+35.9%2273% | 23+152%12554% | 9.0+51.3%— | 5.9−34.5%— | 9.1+369%— | 1.9—— | |
| General and administrative | — | — | — | — | — | — | 9.0+51.3%— | 5.9−34.5%— | 9.1+369%— | 1.9—— | |
| Operating income | −8.9—— | −8.8—— | −15—— | −37—−2756% | −66—−4903% | −64—−35673% | −40—— | −58—— | −98—— | −12—— | |
| Interest and finance income | 0.1+32.2%— | 0.1−81.7%— | 0.3+65.1%— | 0.2+99.0%14.4% | 0.1−15.5%7.3% | 0.1−37.0%64.4% | 0.2−12.8%— | 0.2+75.8%— | 0.1+567%— | 0.0—— | |
| Interest expense and finance costs | — | — | — | 0.0−80.5%1.3% | 0.1+2.4%6.4% | 0.1−58.7%47.2% | 0.2—— | — | — | — | |
| Other non-operating income (expense) | — | — | — | 1.1−17.5%83.0% | 1.4+33900%101% | 0.0—2.2% | 0−100%— | 0.3−65.7%— | 0.9—— | — | |
| Income before tax | −8.6—— | −8.8—— | −14—— | −36—−2673% | −65—−4784% | −64—−35456% | −40—— | −57—— | −96—— | −13—— | |
| Income tax | 0.1−6.3%— | 0.1r−0.1—— | −0.1−156%— | 0.2−95.4%12.1% | 3.6—264% | 0—0.0% | 0—— | — | — | — | |
| Income from discontinued operations | −5.5—— | −7.8—— | −7.9—— | — | — | — | — | — | — | — | |
| Net income including minority interests | −14—— | −17—— | −22—— | −36—−2685% | −68—−5049% | −64—−35456% | −40—— | −57—— | −96—— | −13—— | |
| Minority interests' share of net income | — | — | — | −3.0—−222% | −4.0—−298% | −2.8—−1582% | −2.2—— | −2.6—— | −4.6—— | −0.5—— | |
| Net income attributable to shareholders | −1.0—— | −11—— | −21—— | −33—−2463% | −64—−4750% | −61—−33874% | −38—— | −55—— | −92—— | −12—— | |
| Earnings per share, basic | -0.02—— | -0.28—— | -0.54—— | -0.85—— | -1.64—— | -2.03—— | -1.55—— | -2.42—— | -4.40—— | -0.75—— | |
| Earnings per share, diluted | — | — | — | — | -1.64—— | -2.03—— | -1.55—— | -2.42—— | -4.40—— | -0.75—— | |
| Shares, weighted average (basic) | — | — | — | 39+0.2%— | 39+30.1%— | 30—— | — | — | — | — | |
| Shares, weighted average (diluted) | — | — | — | — | 39+30.1%— | 30+21.7%— | 25+8.7%— | 23+8.6%— | 21+29.7%— | 16—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 7.8+166%30.0% | 2.9−45.8%8.5% | 5.4−84.3%21.8% | 34−17.4%74.4% | 42−62.0%51.0% | 110+205%93.6% | 36+824%80.6% | 3.9−85.8%55.1% | 27+135%83.7% | 12—78.4% | |
| Short-term investments | 4.8—18.4% | 0—0.0% | — | 2.9−90.7%6.2% | 31—37.7% | 0—0.0% | — | — | 3.1—9.4% | — | |
| Other current assets | 0.1+4.4%0.3% | 0.1−59.5%0.2% | 0.2−78.0%0.7% | 0.8−25.2%1.7% | 1.0+185%1.2% | 0.4−12.7%0.3% | 0.4+40.4%0.9% | 0.3+10.6%4.1% | 0.3−26.7%0.8% | 0.4—2.4% | |
| Current assets | 21−26.9%80.5% | 29+55.1%83.3% | 18−52.2%74.2% | 39−48.7%83.3% | 75−33.8%92.0% | 113+178%96.9% | 41+596%91.7% | 5.9−81.8%83.1% | 32+120%98.5% | 15—98.7% | |
| Property, plant and equipment | 0.2−30.5%0.6% | 0.2−24.6%0.7% | 0.3−83.0%1.3% | 1.9+31.4%4.0% | 1.4+673%1.7% | 0.2−12.0%0.2% | 0.2−25.9%0.5% | 0.3+129%4.0% | 0.1+53.8%0.4% | 0.1—0.5% | |
| Right-of-use (leased) assets | 0.3−40.5%1.2% | 0.5−29.7%1.5% | 0.7−86.7%2.9% | 5.5+176%11.9% | 2.0−8.7%2.4% | 2.2−14.3%1.9% | 2.5—5.7% | — | — | — | |
| Non-current assets | 5.1−12.0%19.5% | 5.7−10.2%16.7% | 6.4−17.0%25.8% | 7.7+18.0%16.7% | 6.5+79.4%8.0% | 3.6−1.5%3.1% | 3.7+210%8.3% | 1.2+146%16.9% | 0.5+141%1.5% | 0.2—1.3% | |
| Total assets | 26−24.4%100% | 34+38.3%100% | 25−46.3%100% | 46−43.4%100% | 82−30.2%100% | 117+163%100% | 45+531%100% | 7.1−78.5%100% | 33+120%100% | 15—100% | |
| Accounts payable | 0.4+23.1%1.4% | 0.3−47.4%0.9% | 0.6−48.1%2.3% | 1.1−34.7%2.3% | 1.7−25.3%2.0% | 2.2−12.7%1.9% | 2.5−73.5%5.7% | 9.6+184%136% | 3.4+661%10.3% | 0.4—3.0% | |
| Debt due within a year | — | — | — | 0−100%0.0% | 1.6—1.9% | 0—0.0% | — | — | — | — | |
| Current liabilities | 14+23.3%52.4% | 11+38.4%32.1% | 8.0+8.2%32.1% | 7.4−51.5%15.9% | 15+10.1%18.6% | 14+36.9%11.8% | 10−38.9%22.6% | 16+243%233% | 4.8+83.7%14.6% | 2.6—17.5% | |
| Long-term debt | — | — | — | — | 0−100%0.0% | 2.2+50.9%1.9% | 1.4—3.2% | — | — | — | |
| Lease liabilities (non-current) | 0−100%0.0% | 0.3−47.9%0.9% | 0.6−85.3%2.4% | 4.0+172%8.6% | 1.5+8.0%1.8% | 1.4−29.8%1.2% | 1.9—4.3% | — | — | — | |
| Non-current liabilities | 36−3.3%140% | 38−6.8%110% | 40−3.7%162% | 42+4.4%90.6% | 40+250%49.1% | 11+240%9.8% | 3.4—7.6% | — | — | — | |
| Total liabilities | 50+2.7%193% | 49+0.7%142% | 48−2.0%195% | 49−10.9%107% | 55+119%67.7% | 25+87.9%21.5% | 13−18.4%30.1% | 16+243%233% | 4.8+83.7%14.6% | 2.6—17.5% | |
| Retained earnings | −408—−1575% | −407—−1187% | −396—−1597% | −375—−812% | −342—−419% | −278—−237% | −217—−487% | −179—−2531% | −124—−377% | −32—−216% | |
| Shareholders' equity | −32—−124% | −33—−95.9% | −27—−108% | −6.0−122%−12.9% | 27−69.8%32.7% | 88+192%75.5% | 30—68.0% | −7.8−129%−110% | 27+123%82.5% | 12—81.5% | |
| Minority interests | 8.2−56.1%31.5% | 19—54.2% | −8.5—−34.4% | −8.1—−17.5% | −5.8—−7.1% | −1.7−301%−1.5% | 0.9—1.9% | −1.6−268%−22.9% | 1.0+553%2.9% | 0.1—1.0% | |
| Total equity | −24—−92.5% | −14—−41.6% | −35—−142% | −14−167%−30.5% | 21−75.8%25.6% | 87+178%74.0% | 31—69.9% | −9.4−133%−133% | 28+128%85.4% | 12—82.5% | |
| Total liabilities and equity | 26−24.4%100% | 34+38.3%100% | 25−46.3%100% | 46−43.4%100% | 82−30.2%100% | 117+163%100% | 45+531%100% | 7.1−78.5%100% | 33+120%100% | 15—100% | |
| Shares outstanding | 41+2.0%— | 40+3.3%— | 39+0.1%— | 39+0.2%— | 39−0.5%— | 39+40.4%— | 28+20.3%— | 23+2.9%— | 23+33.5%— | 17—— | |
| Cash-flow statement | |||||||||||
| Share-based compensation | 0.7−68.0%— | 2.3+193%— | 0.8−53.8%— | 1.7−47.1%123% | 3.2−61.5%233% | 8.2+290%4552% | 2.1−68.0%— | 6.6−71.1%— | 23—— | — | |
| Cash from operating activities | −20—— | −16—— | −16—— | −27—−2033% | −47—−3497% | −44—−24303% | −48—— | −40—— | −29—— | −14—— | |
| Capital expenditure | −0.1—— | −0.2—— | −0.1—— | −0.0—−2.5% | −2.8—−211% | −0.1—−28.9% | −0.0—— | −0.2—— | −0.1—— | −0.1—— | |
| Cash from investing activities | 11—— | −12—— | −0.1−101%— | 18—1300% | −20—−1511% | −0.1—−28.9% | −0.0−100%— | 2.9—— | −3.2—— | −0.1—— | |
| Debt issued | 0.3−92.7%— | 3.9—— | 0—— | — | — | — | — | — | — | — | |
| Shares issued | 2.0−33.3%— | 3.0—— | 0—— | 0—0.0% | 0−100%0.0% | 113+62.1%62543% | 69+396%— | 14−72.3%— | 51+231%— | 15—— | |
| Cash from financing activities | 5.0−81.5%— | 27+669525%— | 0.0−99.9%— | 3.4+343000%254% | 0.0−100.0%0.1% | 118+47.0%65464% | 80+505%— | 13−72.2%— | 48+224%— | 15—— | |
| Exchange-rate effect on cash | — | — | — | — | — | — | 0.0−84.5%— | 0.3+1294%— | 0.0—— | −0.1—— | |
| Change in cash | −3.9—— | −1.7—— | −17—— | −7.2—−535% | −68−192%−5027% | 74+130%40891% | 32—— | −24−249%— | 16+1724%— | 0.9—— | |
| Report | 10-K | 10-K | 10-K | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | 20-F | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | |
| Research and development | 4.6—— | 1.0−2.9%— | 1.1+23.1%— | 1.5*—— | 1.0—— | 1.0—— | 0.9—— | |
| Selling, general and administrative | 3.8—— | 0.8−20.0%— | 1.2−33.4%— | 1.1*—— | 0.8—— | 0.9—— | 1.7—— | |
| Operating income | −8.3—— | −1.7—— | −2.2—— | −2.6*—— | −1.8—— | −1.9—— | −2.6—— | |
| Interest and finance income | 0.0—— | 0.0−85.7%— | 0.0−52.9%— | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | |
| Income before tax | −8.0—— | −1.7—— | −2.2—— | −2.5*—— | −1.7—— | −1.9—— | −2.6—— | |
| Income tax | 0.3—— | 0.1+355%— | 0.2+860%— | 0.0*—— | 0.0—— | 0.0—— | 0.0—— | |
| Income from discontinued operations | −15—— | −4.0—— | −4.3−215%— | −3.3*—— | −3.2—— | −2.8—— | 3.8—— | |
| Net income including minority interests | −23—— | −5.7—— | −6.7−670%— | −5.8*—— | −4.9—— | −4.6—— | 1.2—— | |
| Net income attributable to shareholders | −6.7—— | −0.8—— | −2.2−148%— | −2.1*—— | −1.5—— | −1.8—— | 4.5—— | |
| Earnings per share, basic | — | -0.02—— | -0.05−145%— | — | -0.04—— | -0.04—— | 0.11—— | |
| Earnings per share, diluted | — | — | — | — | — | -0.10—— | — | |
| Shares, weighted average (basic) | 41—— | 41+2.0%— | 41+2.0%— | — | 40—— | 40—— | 40—— | |
| Balance sheet | ||||||||
| Cash and cash equivalents | 2.7—18.5% | 2.7−71.7%18.5% | 4.0−38.2%21.9% | 7.8—30.0% | 12—42.3% | 9.5—30.7% | 6.5—17.6% | |
| Short-term investments | 3.8—26.2% | 3.8—26.2% | 3.8+91.3%20.8% | 4.8—18.4% | 0.1—0.5% | — | 2.0—5.4% | |
| Other current assets | 0.3—1.9% | 0.3+36.5%1.9% | 0.2+101%1.0% | 0.1—0.3% | 0.1—0.4% | 0.2—0.6% | 0.1—0.2% | |
| Current assets | 9.9—67.8% | 9.9−61.5%67.8% | 14−57.2%73.4% | 21—80.5% | 24—82.8% | 26—82.8% | 32—85.0% | |
| Property, plant and equipment | 0.1—0.9% | 0.1−31.7%0.9% | 0.2−31.2%0.8% | 0.2—0.6% | 0.2—0.6% | 0.2—0.7% | 0.2—0.6% | |
| Right-of-use (leased) assets | 0.2—1.2% | 0.2−59.6%1.2% | 0.2−51.2%1.3% | 0.3—1.2% | 0.4—1.2% | 0.4—1.4% | 0.5—1.3% | |
| Non-current assets | 4.7—32.2% | 4.7−11.8%32.2% | 4.9−12.1%26.6% | 5.1—19.5% | 5.1—17.2% | 5.3—17.2% | 5.6—15.0% | |
| Total assets | 15—100% | 15−52.9%100% | 18−50.4%100% | 26—100% | 29—100% | 31—100% | 37—100% | |
| Accounts payable | 0.8—5.4% | 0.8+197%5.4% | 0.6+80.4%3.5% | 0.4—1.4% | 0.3—1.0% | 0.3—0.9% | 0.4—1.0% | |
| Current liabilities | 14—97.2% | 14+21.0%97.2% | 12−2.3%67.2% | 14—52.4% | 13—43.7% | 12—37.8% | 13—34.1% | |
| Lease liabilities (non-current) | — | — | — | 0—0.0% | 0.1—0.3% | 0.2—0.5% | 0.2—0.7% | |
| Non-current liabilities | 36—249% | 36−1.1%249% | 36−1.9%198% | 36—140% | 36—123% | 37—119% | 37—100% | |
| Total liabilities | 51—347% | 51+4.2%347% | 49−2.0%265% | 50—193% | 49—167% | 49—157% | 50—134% | |
| Retained earnings | −411—−2817% | −411—−2817% | −411—−2231% | −408—−1575% | −406—−1378% | −405—−1304% | −403—−1086% | |
| Shareholders' equity | −36—−244% | −36—−244% | −34—−187% | −32—−124% | −32—−108% | −30—−97.3% | −28—−76.3% | |
| Minority interests | −0.5—−3.1% | −0.5−104%−3.1% | 4.1−73.6%22.5% | 8.2—31.5% | 12—40.6% | 13—40.8% | 16—42.2% | |
| Total equity | −36—−247% | −36—−247% | −30—−165% | −24—−92.5% | −20—−67.2% | −18—−56.5% | −13—−34.1% | |
| Total liabilities and equity | 15—100% | 15−52.9%100% | 18−50.4%100% | 26—100% | 29—100% | 31—100% | 37—100% | |
| Shares outstanding | 41—— | 41+2.0%— | 41+2.0%— | 41—— | 41r40—— | 40—— | 40—— | |
| Cash-flow statement | ||||||||
| Share-based compensation | 1.4—— | 0.6*+297%— | 0.5+88.9%— | 0.2*—— | 0.2*—— | 0.1*—— | 0.2—— | |
| Cash from operating activities | −17—— | −3.8*—— | −3.3—— | −5.5*—— | −4.2*—— | −5.9*—— | −4.2—— | |
| Capital expenditure | 0—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | −0.1—— | |
| Cash from investing activities | −1.9—— | −0.0*−100%— | 4.5−28.9%— | −5.1*—— | −1.2*—— | 11*—— | 6.3—— | |
| Debt issued | — | — | — | 0.0*—— | — | — | — | |
| Debt repaid | — | −0.1*—— | −4.4—— | — | — | 0*—— | 0—— | |
| Shares issued | — | — | — | 2.0*—— | 0*—— | — | — | |
| Cash from financing activities | 0.7—— | −0.1*—— | −4.2—— | 2.0*—— | 3.0*—— | 0*—— | 0—— | |
| Change in cash | −18—— | −3.8*−177%— | −2.9−239%— | −8.6*—— | −2.4*—— | 5.0*—— | 2.1—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at BeyondSpring Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 2 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 2 · Material agreement 4 · Shareholder vote 2 · Results announced 7
| Filed | What happened | Filing |
|---|---|---|
| Shareholder vote | 8-K | |
| Acquisition or sale completed | 8-K | |
| Delisting notice | 8-K | |
| Material agreement | 8-K | |
| Delisting notice | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K/A | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Acquisition or sale completed | 8-K | |
| Material agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 13, 2026
Lobbying by BeyondSpring Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2024, most often on health issues.
- Health Issues2 reports
Lobbying firms hired in 2024
Farragut Partners LLP $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2024 | $20 K | — | 2 |
| 2023 | $80 K | — | 4 |
| 2022 | $80 K | — | 4 |
| 2021 | $80 K | — | 4 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “BeyondSpring Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How BeyondSpring Inc. compares in Biotechnology
- Market cap$22 M · higher than 18% of 726
- Revenue growth0.0% · higher than 42% of 438
- FCF yield-92.1% · higher than 11% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| BeyondSpring Inc.🇺🇸 | $22 M | — | — | 0.0% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at BeyondSpring Inc.? Verify and update this profile — free
Show BeyondSpring Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.